Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc. reports developments as a pharmaceutical company with commercial generic prescription drugs in Canada and proprietary drug-development programs in oncology and antivirals. News commonly covers product launches through its Nora Pharma subsidiary, including generic medicines such as Domperidone, Doxycycline and Pravastatin, as well as Health Canada commercialization approvals and expansion of therapeutic categories.
The company’s updates also address financial results, portfolio growth and research programs including K1.1 mRNA, an mRNA-lipid nanoparticle candidate targeting liver cancer, and a PLpro protease inhibitor for SARS-related coronavirus infections. Corporate and treasury actions may appear alongside operating updates when they affect Sunshine Biopharma’s capital strategy or public-company profile.
Sunshine Biopharma (NASDAQ:SBFM) reported that its K1.1 mRNA lipid nanoparticle (LNP) program showed in vivo tumor-suppressing activity as a single agent in at least two orthotopic hepatocellular carcinoma (HCC) mouse models, with systemic delivery, dose-dependent restoration of the target tumor suppressor, and good tolerability.
The K1.1 gene is a tumor suppressor frequently mutated in HCC, non-small cell lung cancer (NSCLC), and pancreatic cancer, leading to “cold” tumors. The company also observed antiproliferative effects in several NSCLC cell lines in vitro. The next phase will test concurrent delivery of K1.1 mRNA and a cancer vaccine targeting associated antigens in NSCLC, aiming to convert “cold” tumors into “hot” tumors and suppress growth. Sunshine Biopharma also markets 60 generic drugs in Canada and is advancing a PLpro protease inhibitor for SARS coronavirus infections.
Sunshine Biopharma (NASDAQ:SBFM) has launched its generic Amoxicillin in Canada and has begun shipping to pharmacies, offering multiple dosages and strengths. The move expands the company's portfolio of essential generic antibiotics and supports access to affordable, high-quality treatment for a wide range of bacterial infections.
According to Sunshine Biopharma, global Amoxicillin sales were about $4.9 billion in 2025 and are projected to grow at a 2.9% CAGR to roughly $6.4 billion by 2031. Canada represents approximately 2% of this global market. The company currently markets 60 generic drugs in Canada, with about 12 more launches planned for 2026.
Sunshine Biopharma (NASDAQ:SBFM) received Canadian regulatory approval for its 2mg generic Dienogest tablets, the generic equivalent of Visanne, for treatment of pelvic pain associated with endometriosis.
The company cites Dataintelo, which values the global Dienogest market at $2.8 billion in 2025, projected to reach $5.2 billion by 2034 with a 7.8% CAGR. Canada represents about 2.1% of the global pharmaceutical market and ranks sixth worldwide. Sunshine Biopharma will distribute Dienogest through its wholly owned Canadian subsidiary Nora Pharma and expects product availability for pharmacies by the end of 2026.
According to Sunshine Biopharma, the approval expands its women’s health portfolio. The company currently markets 60 generic prescription drugs in Canada, plans about 12 additional launches in 2026, and is also developing K1.1 mRNA for liver cancer and a PLpro protease inhibitor for SARS coronavirus infections.
Sunshine Biopharma (NASDAQ:SBFM) announced that Health Canada has approved its generic Ondansetron 4mg and 8mg tablets, including standard film-coated and Oral Disintegrating Tablet (ODT) forms, for the Canadian market. Ondansetron is the generic equivalent of Zofran® and is prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery.
According to Sunshine Biopharma, the launch expands its portfolio into chemotherapy‑related nausea and vomiting, leveraging its Canadian distribution network via subsidiary Nora Pharma. The company expects Ondansetron to be ready for shipment to pharmacies by the end of 2026 and currently markets 60 generic drugs in Canada, with about 12 more scheduled for launch in 2026.
Sunshine Biopharma (NASDAQ:SBFM) announced peer‑reviewed publication in the Journal of Medicinal Chemistry of research on MR1‑114, a novel noncovalent PLpro inhibitor for SARS‑CoV‑2. MR1‑114 showed nanomolar potency in vitro across multiple variants, including the Washington strain, Delta and Omicron BA.5.
According to Sunshine Biopharma, MR1‑114 demonstrated broad‑spectrum activity, favorable ADME properties, high oral bioavailability and preferential lung enrichment in mice and rats. In the K18‑hACE2 mouse model, repeated oral dosing matched the therapeutic efficacy of Nirmatrelvir by significantly suppressing pulmonary viral replication and preventing disease‑associated weight loss.
The work, conducted with the University of Arizona, is described as an important milestone in Sunshine Biopharma’s PLpro inhibitor program for SARS Coronavirus infections. The company also highlights a commercial portfolio of 60 generic prescription drugs in Canada, with about 12 additional launches planned for 2026 and a K1.1 mRNA program for liver cancer.
Sunshine Biopharma (NASDAQ:SBFM) received Canadian regulatory approval for its 1mg generic Anastrozole tablets, the equivalent of breast cancer drug Arimidex®. Anastrozole is a standard adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer.
The company will distribute in Canada via subsidiary Nora Pharma and expects to ship before end of 2026.
Sunshine Biopharma (NASDAQ:SBFM) announced Canadian approval of its generic Rivaroxaban tablets in 2.5mg, 10mg, 15mg and 20mg strengths, a generic equivalent of Xarelto®.
The drug will be distributed through Nora Pharma in Canada, expands the company’s anticoagulant portfolio alongside Apixaban, and is anticipated to ship in October 2026.
Sunshine Biopharma (NASDAQ:SBFM) announced issuance of U.S. Patent 12,624,066 B2 covering proprietary small-molecule compounds for treatment of coronavirus infection. The patent protects PLpro enzyme inhibitors designed to block viral replication and immune suppression. Compounds are ready for GLP studies, the final step before entering clinical trials.
Sunshine Biopharma (NASDAQ:SBFM) approved a 1-for-10 reverse stock split of its common shares, effective at market open on June 1, 2026. The action aims to regain compliance with Nasdaq’s minimum bid price requirement and will reduce outstanding shares from 21,236,346 to approximately 2,123,635.
Sunshine Biopharma (NASDAQ:SBFM) received Canadian regulatory approval for its generic Amoxicillin, supporting its strategy in generic antibiotics. The product will be offered in multiple dosage forms and strengths and is anticipated to ship to Canadian pharmacies in August 2026.
Amoxicillin global sales were estimated at $4.9–$5.9 billion in 2025, with 2.9% CAGR projected to about $6.4 by 2031. Canada represents roughly 2% of global Amoxicillin sales.